Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1C | Q13936 | 4/20 | 0.64 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.64 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.64 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.54 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.54 |
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | TSHR | P16473 | 3/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6945806 | 0.97 | CACNA1C (0.59) | CACNA1CCACNA1FCACNA1DCACNA1SCYP2C9 | |
| SCHEMBL6949620 | 0.93 | CACNA1C (0.55) | CACNA1CCACNA1FCACNA1DCACNA1SCYP2C9 | |
| SCHEMBL6953226 | 0.90 | CACNA1C (0.57) | CACNA1CCACNA1FCACNA1DCACNA1SCYP2C9 | |
| SCHEMBL6953550 | 0.87 | CACNA1F (0.50) | CACNA1CCACNA1FCACNA1DCACNA1SMAPT | |
| SCHEMBL11781966 | 0.84 | CACNA1C (0.67) | CACNA1CCACNA1FCACNA1DCACNA1S | |
| SCHEMBL9173126 | 0.83 | CACNA1C (0.75) | CACNA1CCACNA1FCACNA1DCACNA1SCYP2C9 | |
| SCHEMBL10823933 | 0.83 | CACNA1C (0.64) | CACNA1CCACNA1FCACNA1DCACNA1SCYP2C9 | |
| SCHEMBL9177270 | 0.83 | CACNA1C (0.74) | CACNA1CCACNA1FCACNA1DCACNA1SCYP2C9 | |
| SCHEMBL7431449 | 0.81 | CACNA1C (0.78) | CACNA1CCACNA1FCACNA1DCACNA1SCYP2C9 | |
| SCHEMBL10823959 | 0.81 | ADORA3 (0.71) | CACNA1CCACNA1FCACNA1DCACNA1SCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0657432-B1 | Phenyl-substituted 1,4-dihydropyridines with cerebral activity | BAYER AG (DE) | 2003-03-12 | — | — | EP | claimed |
| US-6630494-B2 | Treatment for central degenerative disorders, brain power disorders, depressions, and for prophylaxis of cerebral circulatory disorders | BAYER AKTIENGESELLSCHAFT (DE) | 2003-10-07 | — | — | US | disclosed |
| US-20010034451-A1 | Phenyl-substituted 1,4-dihydropyridines | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2001-10-25 | — | — | US | disclosed |
| US-6239155-B1 | TREATMENT OF CENTRAL DEGENERATIVE DISORDERS, AS DEMENTIAS, ALZHEIMER'S DISEASE, PARKINSON'S DISEASE OR AMYOTROPHIC LATERAL SCLEROSIS, MEMORY IMPAIRMENT, DEPRESSIONS, MIGRAINE, OF NEUROPATHIES, METABOLIC DISORDERS SUCH AS DIABETES | BAYER AKTIENGESELLSCHAFT (DE) | 2001-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010034451-A1 | Phenyl-substituted 1,4-dihydropyridines | GRIK4, PKM, PDK4 | CACNA1C 724/4885CACNA1F 658/4885CACNA1D 331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.